evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

476 questions · 488 findings · 43 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 134 · 27.5%GRADE not reported 21 · 4.3%Very low 91 · 18.6%Low 135 · 27.7%Moderate 78 · 16%High 29 · 5.9%

Summary of findings: pioglitazone monotherapy vs no intervention

All‐cause mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs no intervention

Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy probably leads to lower incidence of T2DM (N) Diagnostic criteria: 9 studies applied the WHO… compared with no intervention (moderate certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs no intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).

1 finding from 1 review